In the new year and new atmosphere, enterprises in major industries are actively launching new layouts
.
Tianyancha App shows that recently, Oriental Preferred (Beijing) Technology Co.
, Ltd.
, an affiliate of Oriental Selection, has undergone industrial and commercial changes, and its business scope has added Class III medical device business; wholesale of medicines; pharmaceutical retail; Medical mask retail, etc
.
According to the data, Oriental Preferred (Beijing) Technology Co.
, Ltd
.
was established in October 2021 and is wholly owned by Beijing New Oriental Xuncheng Network Technology Co.
, Ltd.
The analysis believes that the company's entry into the pharmaceutical retail industry is behind its considerable market space
.
In fact, recently, the pharmaceutical retail industry has once again entered people's field of vision due to the formal implementation of "Class B tube", attracting the attention
of the industry.
At present, the pharmaceutical retail industry has entered a new stage, and the integration of online and offline has become an innovative development model
for pharmaceutical retail enterprises.
In early December 2022, the "Measures for the Supervision and Administration of Online Sales of Drugs" was officially implemented, which means that Internet drug sales ushered in an era of strong supervision, which will force offline pharmacies to accelerate reform and upgrading, expand the service radius through new business models such as Internet medical treatment, B2C, and O2O, and provide emerging growth momentum for the industry, and the industry expects that the Internet + sales model will become a new trend
in the development of retail pharmacies in the future.
With the improvement of residents' consumption level, the aging of the population, the acceleration of medical consumption upgrading, and the advancement of a new round of pharmaceutical reform, China's pharmaceutical retail industry has developed rapidly, and the market scale of the industry is expected to expand.
Data show that China's drug terminal market has increased from 809.
7 billion yuan in 2011 to 1,643.
7 billion yuan in 2020, with a compound annual growth rate of 8.
18%.
According to Frost & Sullivan's forecast, the pharmaceutical retail industry will maintain a stable growth trend in the future, and the total terminal market size of pharmaceutical and non-pharmaceutical products will exceed 6 trillion yuan by 2030, reaching 6,175 billion yuan
.
Aiming at the huge market, more and more pharmaceutical companies and cross-border enterprises have entered the market
.
In addition to Oriental Preferred, for example, in September 2022, the business scope of China Resources Vanguard, which is mainly engaged in the retail industry, has changed and added drug retail, which is only implemented in some stores of the Guangdong company; In January 2021, Xinxing County Lianxing New Energy Co.
, Ltd.
added business scope such as "gas business, drug retail, Class III medical device business, Class I medical device sales, and Class II medical device sales"; In April 2020, Yonghui Supermarket Co.
, Ltd.
, the operating entity of Yonghui Supermarket, changed its business scope and added an online trade agent; Internet retail, etc
.
It is worth mentioning that at present, the domestic pharmaceutical retail industry as a whole presents the characteristics of low chain rate and low concentration, as of the end of September 2021, there are 606,500 enterprises licensed by the "Drug Business License" in the country, including 13,400 wholesale enterprises; There are 6,658 retail chain enterprises, 335,300 retail chain stores, and 251,200 single pharmacies
.
Compared with developed countries, the chain rate of China's pharmaceutical retail industry is obviously low
.
The industry expects that with the promotion of medical reform policies such as drug proportion, zero difference rate, medical insurance control fee, graded diagnosis and treatment, consistency evaluation, volume procurement, dual-channel, DRG payment reform, etc.
, to guide the pharmaceutical retail chain operation, the future pharmaceutical retail market concentration and retail chain rate are expected to continue to increase, competition will become increasingly fierce, and the huge market space may be divided
by more competitive head enterprises.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
